cemka > Publications > Rhumatologie

Classer les publications sur l'année

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study

    SARAUX A, FLIPO R-M, FAGNANI F, MASSOL J, CUKIERMAN G, JOUBERT J-M , HUOT-MARCHAND P, COMBE B

    BMJ Journals ; 2020;6 (1)

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Trends in postmenopausal osteoporosis treatment in France during the period 2007-2016: A nationwide claim database analysis.

    CORTET B, SCHOTT AM, DESAMERICQ G, CHAUNY JV, SAMAMA P, EMERY C, FAGNANI F.

    Bone ; 2022;154:116255

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Profile of Women Initiated on Denosumab and Pattern of Use in a Restricted Postmenopausal Osteoporosis Indication: A French Database Analysis Over the Period 2013-2014.

    EMERY C, GOURMELEN J, FAGNANI F, SUZAN F, DESAMERICQ G, FARDELLONE P.

    Adv Ther ; 2019;36(4),969-975

  • Économie de la santĂ©

    Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost.

    CLAUDEPIERRE P, FAGNANI F, CUKIERMAN G, DE CHALUS T, JOUBERT JM, LAURENDEAU C, GOURMELEN J, BREBAN M

    Joint Bone Spine ; 2019;86(1);69-75

  • Pharmaco-EpidĂ©miologie

    Epidemiology, impact, management and cost of Paget’s disease of bone in France

    SARAUX A, BRUN-STRANG C, MIMAUD V, VIGNERON AM, LAFUMA A

    Joint Bone Spine ; 74(1):90-95

  • Économie de la santĂ©

    A model of the public health impact of improved treatment persistence in post-meopausal osteoroposis in France

    COTTE FE, CORTET B, LAFUMA A, AVOUAC B, HASNAOUI AE, FADELLONE P, POUCHAIN D, ROUX C, GAUDIN AF

    Joint Bone Spine ; 31

  • Économie de la santĂ©

    Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries

    BOUEE S, LAFUMA A, FAGNANI F, MEUNIER PJ, REGINSTER JY

    Rheumatol Int ; 26(12):1063-72

  • Pharmaco-EpidĂ©miologie

    Costs of rheumatoid arthritis in France : a multicenter study of 1109 patients managed by hospital-based rheumatologists

    GUILLEMIN F, DURIEUX S, DAURES JP, LAFUMA A, SARAUX A, SIBILIA J, BOURGEOIS P, SANY J

    J Rheumatol ; 31(7):1297-1304

  • Pharmaco-EpidĂ©miologie

    Characteristics of patients with rheumatoid arthritis in France : a study of 1109 patients managed by hospital based rhumatologists

    SANY J, BOURGEOIS P, SARAUX A, DURIEUX S, LAFUMA A, DAURES JP, GUILLEMIN F, SIBILIA J

    Ann Rheum Dis ; 63(10):1235-1240

  • Pharmaco-EpidĂ©miologie

    Prevalence of Gout in the Adult Population of France.

    BARDIN T, BOUEE S, CLERSON P, CHALES G, FLIPO RM, LIOTE F, PEREZ V, POIRAUD T, SCHAEVERBEKE T, RICHETTE P.

    Arthritis Care Res ; 2016;68(2):261-6

  • Pharmaco-EpidĂ©miologie

    Impact of rheumatoid arthritis on career progression, productivity, and employability: The PRET Study

    BERTIN P, FAGNANI F, DUBURCQ A, WORONOFF AS, CHAUVIN P, CUKIERMAN G, TROPÉ-CHIROL S, JOUBERT JM, KOBELT G

    Joint Bone Spine ; 2016;83(1):47-52

  • Pharmaco-EpidĂ©miologie

    Identification of patients with gout: elaboration of a questionnaire for epidemiological studies.

    RICHETTE P, CLERSON P, BOUÉE S, CHALÈS G, DOHERTY M, FLIPO RM, LAMBERT C, LIOTE F, POIRAUD T, SCHAEVERBEKE T, BARDIN T.

    Ann Rheum Dis ; 2015;74(9);1684-1690

  • Pharmaco-EpidĂ©miologie

    Biomechanical and psychosocial work exposures and musculoskeletal symptoms among vineyard workers

    BERNARD C, COUROUVE L, BOUEE S, ADJEMIAN A, CHRETIEN JC, NIEDHAMMER I

    J Occup Health ; 2011;53:297-311